<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311896</url>
  </required_header>
  <id_info>
    <org_study_id>ICT-BEM-2004-02</org_study_id>
    <secondary_id>BECAT</secondary_id>
    <nct_id>NCT00311896</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)</brief_title>
  <official_title>Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorio farmacéutico ROVI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the subcutaneous
      administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to
      prevent CVC-related deep venous thrombosis (CVC-DVT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolism (VTE) is a common complication in patients with cancer principally in
      association with central vein catheters (CVC). The clinical benefit of antithrombotic
      prophylaxis for CVC-related VTE in cancer patients remains unclear.The aim of this study is
      to evaluate the efficacy and safety of the administration of Bemiparin in cancer patients
      with a central venous catheter (CVC). This study is designed as a multicenter, randomized,
      double-blind, placebo-controlled study. On the day of CVC insertion, eligible patients are
      randomly assigned to receive subcutaneously either bemiparin (3,500 UI/day) or placebo by
      using preloaded syringes for 45 days.

      The primary efficacy endpoint will be the combined incidence during the double blind
      treatment period of Clinical or symptomatic CVC-DVT verified objectively (Doppler
      ultrasonography or phlebography)and subclinical or asymptomatic CVC-DVT confirmed by elective
      bilateral Doppler ultrasonography performed 45±5 days after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor stopped due to difficulties to recruit 402 patients required by protocol
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical or symptomatic CVC-DVT verified objectively (Doppler ultrasonography or phlebography).</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Subclinical or asymptomatic CVC-DVT confirmed by elective bilateral Doppler ultrasonography performed 45±5 days after randomization.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Cancer</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Bemiparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <arm_group_label>Bemiparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old of either sex who have given their informed consent to
             participate in the study.

          -  Patients with a neoplastic process, with a CVC for the administration of anti-tumoral
             treatment or any other treatment related to the neoplastic process.

          -  Patients with a platelet count above 30,000/mm3.

          -  Patients with no hemorrhagic symptomatology at the time of their inclusion

        Exclusion Criteria:

          -  Patients with a history of clinically evident hemorrhagic episodes and/or with
             increased bleeding due to any other homeostatic alteration that contraindicates
             anticoagulant treatment and/or in the past two months have presented at least one of
             the following: active hemorrhaging or organic lesions susceptible to bleeding (e.g.
             active peptic ulcer, hemorrhagic cerebrovascular accident, aneurysms).

          -  Major surgery in the past two months.

          -  Known hypersensitivity to LMWH, heparin or substances of porcine origin.

          -  Patients with congenital or acquired bleeding diathesis.

          -  Damage to or surgical interventions of the central nervous system, eyes and ears
             within the past 6 months.

          -  Acute bacterial endocarditis or slow endocarditis.

          -  Patients with a history of heparin-associated thrombocytopenia.

          -  Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic
             insufficiency (with values of AST and/or ALT &gt; 5 times the normal value established by
             the reference range of the local hospital laboratory).

          -  Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
             blood pressure over 120 mmHg).

          -  Patients with suspected inability/or inability to comply with treatment and/or
             complete the study.

          -  Patients who are participating in another clinical trial or have done so in the past
             30 days.

          -  Patients with a life expectancy less than 3 months.

          -  Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant
             during the study.

          -  Patients on treatment with anticoagulants or who have been on treatment during the
             week previous to insert the CVC (including prophylaxis with heparin for hepatic
             veno-occlusive disease).

          -  Patients diagnosed with acute leukemia or awaiting a transplant from hematopoietic
             progenitors during the 90 days of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Rocha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Lecumberri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Vicente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascual Marco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Mateo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Font, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Arratibel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco J. Capote, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Angel De gregorio Ariza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario Lozano Blesa-Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Picón Roig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo González Del Val Subirats, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Bosh Roig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Doctor Peset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Pérez-Segura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos-Madrid.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Alberola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>César Rodríguez Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Alberca Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier García Frade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Río Hortega</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Sedano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natividad Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amalia Velasco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Rodríguez Pinto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Central de Asturias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mihai Ciochinaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cenral Emergency Clinical Military H.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cornelia Toganel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>District Emergency Clinical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Csaba Bela Szekely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arad District Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mihaela Danciulescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Filantropia District Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Constantin Volovat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Medical Center Iasi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mircea Cazacu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University &quot;CF&quot; Clinical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eliade Ciuleanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Institute Cuj-Napoca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florin Bacanu, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sf Maria Clinical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arad County Hospital</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cenral Emergency Clinical Military H.</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf Maria Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute Cuj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University &quot;CF&quot; Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Filantropia District Hospital</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Medical Center, Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Emergency Clinical Hospital</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos-Madrid.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Catheter</keyword>
  <keyword>Bemiparin</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

